ARCH Venture led a $167m Series C funding round in Nutcracker Therapeutics.

ARCH Venture, an early stage venture capital, led a $167m Series C funding round in Nutcracker Therapeutics, a biotech company developing RNA therapeutics using its proprietary biochip-based manufacturing platform. “With this significant milestone and the support of our top-flight investors and partners, we are well-positioned to begin the next phase of Nutcracker’s evolution: accelerating RNA therapeutics development within the company and beyond using our unique ‘GMP-in-a-box’ platform, and meet the rising demand for RNA therapies and their efficient, scalable manufacturing," Igor Khandros, Nutcracker Therapeutics Co-Founder and CEO.